ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,090,264 | +172.7% | 100,306 | +214.4% | 0.00% | +200.0% |
| Q2 2023 | $766,515 | +66.1% | 31,909 | +29.3% | 0.00% | 0.0% |
| Q1 2023 | $461,388 | +31.8% | 24,675 | +12.2% | 0.00% | 0.0% |
| Q4 2022 | $350,000 | -7.2% | 21,986 | -4.3% | 0.00% | 0.0% |
| Q3 2022 | $377,000 | +17.1% | 22,984 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $322,000 | -33.2% | 22,875 | -3.4% | 0.00% | 0.0% |
| Q1 2022 | $482,000 | -22.6% | 23,675 | -10.6% | 0.00% | 0.0% |
| Q4 2021 | $623,000 | +54.6% | 26,485 | +10.0% | 0.00% | 0.0% |
| Q3 2021 | $403,000 | -36.0% | 24,086 | -6.2% | 0.00% | 0.0% |
| Q2 2021 | $630,000 | -9.6% | 25,679 | -4.7% | 0.00% | -50.0% |
| Q1 2021 | $697,000 | -56.1% | 26,946 | -9.4% | 0.00% | -50.0% |
| Q4 2020 | $1,589,000 | +20.3% | 29,752 | -3.9% | 0.00% | 0.0% |
| Q3 2020 | $1,321,000 | +11.9% | 30,968 | +27.0% | 0.00% | 0.0% |
| Q2 2020 | $1,180,000 | +16.5% | 24,375 | +2.3% | 0.00% | 0.0% |
| Q1 2020 | $1,013,000 | – | 23,830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |